{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:20:01Z","timestamp":1790706001232,"version":"4.1.0"},"reference-count":48,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Multiple myeloma (MM) is characterized by kidney deficiency, phlegm, and blood stasis as core findings, specifically in Traditional Chinese Medicine (TCM), and the kidney-tonifying, phlegm-resolving, and blood stasis\u2013removing (KPR) method is a fundamental therapeutic approach for MM in TCM. Western medicine primarily focuses on targeted immunotherapy or chemotherapy for MM treatment, whereas TCM characterizes MM through distinct pathological patterns that directly correspond to immune microenvironment dysregulation. Emerging evidence implicates the PHD finger protein 19 (PHF19)\/enhancer of zeste homolog 2 (EZH2)\/trimethylated histone H3 at lysine 27 (H3K27me3) epigenetic axis in immune microenvironment dysregulation and MM progression. Notably, TCM \u201cblood stasis\u201d correlates with hypoxia-induced immune gene silencing in MM bone marrow, and KPR (a clinically validated TCM decoction with 16 herbs) acts on this axis via its active components that regulate EZH2 and epigenetic function, merging TCM syndrome differentiation with modern epigenetics. We have designed a randomized controlled trial (RCT) to investigate the mechanism of action and safety of the KPR method in MM.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This RCT aims to assess whether a KPR herbal formula combined with standard bortezomib-based therapy improves the immune microenvironment via the PHF19-EZH2-H3K27me3 epigenetic axis to restore immune function in MM, providing a mechanistic basis for integrating TCM into evidence-based oncology care in relapsed or refractory patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This is a single-center, prospective RCT involving patients with MM. It has been designed to test the hypothesis that the KPR formula epigenetically regulates the PHF19-EZH2-H3K27me3 axis to improve the immune microenvironment. Patients are randomly assigned in a 1:1:1 ratio to 3 groups (blank control group, Western medicine control group, and integrated TCM and Western medicine treatment group). All patients undergo 12 weeks of treatment and a 6-month follow-up. The primary outcome is the CD3\n +<\/jats:sup>\n T-cell ratio in bone marrow\/peripheral blood, which is detected by flow cytometry. The secondary outcomes include quantified TCM syndrome scores, Western medicine efficacy evaluation criteria, complete blood count, bone marrow morphology, blood and urine immunoglobulin levels, quantitative M protein levels, free light chain levels, \u03b22-microglobulin levels, and whole-body imaging findings. Statistical analysis involves linear mixed models for longitudinal data and Bonferroni correction to verify KPR\u2019s immunomodulatory effects via the targeted epigenetic axis.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study was funded in November 2023. Recruitment was initiated in March 2025 and is expected to be completed in February 2026. As of October 2025, 41 patients have been enrolled. Data collection is projected to end in October 2026. Data analysis has not yet been initiated, and the results are expected to be published in 2027.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This unique mechanistic RCT evaluating a TCM formula targeting the PHF19-EZH2-H3K27me3 axis in patients with MM will establish a biomarker-driven framework for integrating TCM with immunotherapy, offering novel strategies for treatment-refractory patients.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/86322","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:30:12Z","timestamp":1773282612000},"page":"e86322-e86322","source":"Crossref","is-referenced-by-count":2,"title":["Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis\u2013Removing Therapy for Multiple Myeloma: Protocol for a Randomized Controlled Trial on Epigenetic and Immune Modulation"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-8309","authenticated-orcid":false,"given":"Xiaoqi","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7384-5526","authenticated-orcid":false,"given":"Yongming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4520-0712","authenticated-orcid":false,"given":"Yujue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8439-8918","authenticated-orcid":false,"given":"Youya","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5365-3854","authenticated-orcid":false,"given":"Wenwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8885-9714","authenticated-orcid":false,"given":"Hailin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"5","key":"R1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","journal-title":"JAMA"},{"issue":"6","key":"R2","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/CCO.0000000000000677","article-title":"Immunotherapy in multiple myeloma: when, where, and for who?","volume":"32","author":"Verkleij","journal-title":"Curr Opin Oncol"},{"issue":"6","key":"R3","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-022-03365-1","article-title":"Novel immunotherapies in multiple myeloma","volume":"115","author":"Ohmine","journal-title":"Int J Hematol"},{"issue":"10192","key":"R4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","journal-title":"The Lancet"},{"issue":"6","key":"R5","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1016\/S2352-3026(22)00103-X","article-title":"Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial","volume":"9","author":"Dimopoulos","journal-title":"Lancet Haematol"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221104584","article-title":"Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone and carfilzomib-dexamethasone in relapsed\/refractory multiple myeloma: a multicenter retrospective analysis","volume":"13","author":"Onda","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"R7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1053\/j.seminoncol.2022.01.008","article-title":"Daratumumab: a review of current indications and future directions","volume":"49","author":"Hill","journal-title":"Semin Oncol"},{"issue":"5","key":"R8","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s11523-021-00827-0","article-title":"Isatuximab: a review of its use in multiple myeloma","volume":"16","author":"Frampton","journal-title":"Targ Oncol"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/ejh.13723","article-title":"Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients","volume":"108","author":"Morabito","journal-title":"Eur J Haematol"},{"issue":"1","key":"R10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.20517\/cdr.2021.116","article-title":"Drug resistance and minimal residual disease in multiple myeloma","volume":"5","author":"Gozzetti","journal-title":"Cancer Drug Resist"},{"issue":"2","key":"R11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.20517\/cdr.2022.32","article-title":"Cancer drug resistance in multiple myeloma","volume":"5","author":"Uckun","journal-title":"Cancer Drug Resist"},{"issue":"3","key":"R12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031649","article-title":"Multiple myeloma: challenges encountered and future options for better treatment","volume":"23","author":"Das","journal-title":"Int J Mol Sci"},{"issue":"14","key":"R13","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1182\/blood.2019000578","article-title":"PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation","volume":"134","author":"Ren","journal-title":"Blood"},{"issue":"7","key":"R14","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1038\/s41375-020-0742-z","article-title":"Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease","volume":"34","author":"Mason","journal-title":"Leukemia"},{"issue":"3","key":"R15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.molcel.2012.11.026","article-title":"An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting","volume":"49","author":"Cai","journal-title":"Mol Cell"},{"issue":"1","key":"R16","first-page":"200","volume":"10","author":"Ning","journal-title":"Am J Transl Res"},{"issue":"16","key":"R17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164069","article-title":"Investigating the interplay between myeloma cells and bone marrow stromal cells in the development of drug resistance: dissecting the role of epigenetic modifications","volume":"13","author":"Sch\u00fctt","journal-title":"Cancers (Basel)"},{"issue":"3","key":"R18","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.27","article-title":"Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control","volume":"7","author":"Pawlyn","journal-title":"Blood Cancer J"},{"issue":"2","key":"R19","doi-asserted-by":"publisher","first-page":"188700","DOI":"10.1016\/j.bbcan.2022.188700","article-title":"EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy","volume":"1877","author":"Sun","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"2","key":"R20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","journal-title":"Cancers (Basel)"},{"issue":"4","key":"R21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1158\/2643-3230.BCD-21-0205","article-title":"Perspectives on the risk-stratified treatment of multiple myeloma","volume":"3","author":"Davies","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"R22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.16808\/j.cnki.issn1003-7705.2020.03.065","article-title":"\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9aa8\u75c5\u7684\u4e2d\u897f\u533b\u7814\u7a76\u8fdb\u5c55 (Advances in Traditional Chinese and Western medicine research on multiple myeloma bone disease) [Article in Chinese]","volume":"36","author":"Wei","journal-title":"Hunan Journal of Traditional Chinese Medicine"},{"issue":"8","key":"R23","first-page":"10","volume":"40","author":"Dan","journal-title":"Hubei Journal of Traditional Chinese Medicine"},{"issue":"20","key":"R24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.19613\/j.cnki.1671-3141.2019.20.131","article-title":"\u6d45\u8c08\u4e2d\u533b\u5bf9\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7684\u8ba4\u8bc6 [Article in Chinese]","volume":"19","author":"Yaling","journal-title":"\u4e16\u754c\u6700\u65b0\u533b\u5b66\u4fe1\u606f\u6587\u6458"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00531","article-title":"Anti-myeloma effects of icariin are mediated through the attenuation of JAK\/STAT3-dependent signaling cascade","volume":"9","author":"Jung","journal-title":"Front Pharmacol"},{"issue":"1","key":"R26","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05013-0","article-title":"Targeting of mitochondrial fission through natural flavanones elicits anti-myeloma activity","volume":"22","author":"Torcasio","journal-title":"J Transl Med"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.05.038","article-title":"Formononetin-induced oxidative stress abrogates the activation of STAT3\/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model","volume":"431","author":"Kim","journal-title":"Cancer Lett"},{"issue":"12","key":"R28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.13193\/j.issn.1673-7717.2024.12.035","article-title":"\u57fa\u4e8e\u5355\u7ec6\u80de\u6c34\u5e73\u7684\u8865\u80be\u4e2d\u836f\u8c03\u63a7\u9aa8\u91cd\u5efa\u4f5c\u7528\u673a\u5236\u63a2\u8ba8\u80be\u4e3b\u9aa8\u751f\u9ad3\u7684\u79d1\u5b66\u5185\u6db5 (Exploring scientific connotation of kidney dominating bone and producing marrow regulating mechanism of bone remodeling by kidney-tonifying Chinese Medicine based on single cell level) [Article in Chinese]","volume":"42","author":"Xinyi","journal-title":"Chinese Archives of Traditional Chinese Medicine"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117157","article-title":"Baicalin promotes anti-tumor immunity in hepatocellular carcinoma through HIF-1\u03b1\/lactate\/CXCL9 axis","volume":"241","author":"Yang","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"R30","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/tox.21763","article-title":"Scutellaria barbata inhibits angiogenesis through downregulation of HIF-1 \u03b1 in lung tumor","volume":"29","author":"Shiau","journal-title":"Environ Toxicol"},{"issue":"2","key":"R31","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.yexcr.2014.09.018","article-title":"HIF-1\u03b1 inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment","volume":"328","author":"Borsi","journal-title":"Exp Cell Res"},{"issue":"7","key":"R32","doi-asserted-by":"publisher","first-page":"114394","DOI":"10.1016\/j.celrep.2024.114394","article-title":"UBR7 in concert with EZH2 inhibits the TGF-\u03b2 signaling leading to extracellular matrix remodeling","volume":"43","author":"Adhikari","journal-title":"Cell Rep"},{"issue":"1","key":"R33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39845-z","article-title":"Lysine methylation promotes NFAT5 activation and determines temozolomide efficacy in glioblastoma","volume":"14","author":"Li","journal-title":"Nat Commun"},{"issue":"7","key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/j.psj.2021.101129","article-title":"Polysaccharide of atractylodes macrocephala koidz activated T lymphocytes to alleviate cyclophosphamide-induced immunosuppression of geese through novel_mir2\/CD28\/AP-1 signal pathway","volume":"100","author":"Li","journal-title":"Poult Sci"},{"issue":"10","key":"R35","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41388-019-1132-8","article-title":"A TGF-\u03b2-MTA1-SOX4-EZH2 signaling axis drives epithelial-mesenchymal transition in tumor metastasis","volume":"39","author":"Li","journal-title":"Oncogene"},{"issue":"105","key":"R36","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adm8251","article-title":"DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity","volume":"10","author":"Li","journal-title":"Sci Immunol"},{"issue":"11","key":"R37","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07109-3","article-title":"Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI\/SNF loss-of-function tumors","volume":"15","author":"Wang","journal-title":"Cell Death Dis"},{"issue":"10","key":"R38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102348","article-title":"The multiple myeloma landscape: epigenetics and non-coding RNAs","volume":"14","author":"Coira","journal-title":"Cancers (Basel)"},{"issue":"1","key":"R39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3892\/or.2015.3957","article-title":"MicroRNA-195-5p acts as an anti-oncogene by targeting PHF19 in hepatocellular carcinoma","volume":"34","author":"Xu","journal-title":"Oncol Rep"},{"issue":"1","key":"R40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09882-8","article-title":"miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8 T cell fate","volume":"10","author":"Ji","journal-title":"Nat Commun"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-025-09351-x","article-title":"Intratumoral microbe correlated with expression of DNA methylation genes in hepatocellular carcinoma","author":"Kumar","journal-title":"Dig Dis Sci"},{"issue":"1","key":"R42","first-page":"224","volume":"19","journal-title":"\u8fbd\u5b81\u4e2d\u533b\u836f\u5927\u5b66\u5b66\u62a5"},{"key":"R43","unstructured":"Declaration of Helsinki \u2013 Ethical principles for medical research involving human participants. World Medical Association. 2024. URL: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/World [Accessed 20-02-2026]"},{"issue":"6","key":"R44","doi-asserted-by":"publisher","first-page":"160","DOI":"10.13193\/j.issn.1673-7717.2020.06.038","article-title":"\u6d3b\u8840\u9010\u7600\u65b9\u8054\u5408\u5316\u7597\u6cbb\u7597\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u4e34\u5e8a\u7597\u6548\u53ca\u5bf9\u673a\u4f53\u514d\u75ab\u529f\u80fd\u7684\u5f71\u54cd (Clinical observation of Huoxue Zhuyu decoction combined with chemotherapy in treatment of multiple myeloma and its effect on immune function) [Article in Chinese]","volume":"38","author":"Huiying","journal-title":"Chinese Archives of Traditional Chinese Medicine"},{"issue":"11","key":"R45","first-page":"45","volume":"46","author":"Jianling","journal-title":"Shanghai Medical and Pharmaceutical Journal"},{"issue":"1","key":"R46","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0389-8","article-title":"Design considerations for early-phase clinical trials of immune-oncology agents","volume":"6","author":"Wages","journal-title":"J Immunother Cancer"},{"issue":"1","key":"R47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.12793\/tcp.2022.30.e2","article-title":"Comparison of international guidelines for early-phase clinical trials of cellular and gene therapy products","volume":"30","author":"Shin","journal-title":"Transl Clin Pharmacol"},{"issue":"5","key":"R48","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3872\/j.issn.1007-385X.2016.05.024","article-title":"\u8868\u89c2\u9057\u4f20\u4fee\u9970\u5728\u80bf\u7624\u514d\u75ab\u6cbb\u7597\u4e2d\u7684\u610f\u4e49 (Significance of the epigenetic modifications in cancer immunotherapy) [Article in Chinese]","volume":"23","author":"You","journal-title":"Chinese Journal of Cancer Biotherapy"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e86322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:14:16Z","timestamp":1782839656000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e86322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":48,"URL":"https:\/\/doi.org\/10.2196\/86322","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"article-number":"v15i5e86322"}}